Caerus Investment Advisors LLC Invests $636,000 in Medtronic PLC $MDT

Caerus Investment Advisors LLC bought a new position in Medtronic PLC (NYSE:MDT) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 6,674 shares of the medical technology company’s stock, valued at approximately $636,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MDT. Delos Wealth Advisors LLC acquired a new stake in Medtronic during the second quarter worth about $27,000. Corundum Trust Company INC purchased a new position in shares of Medtronic in the 3rd quarter worth about $27,000. Valley Wealth Managers Inc. acquired a new position in shares of Medtronic in the 3rd quarter valued at about $29,000. Imprint Wealth LLC acquired a new position in shares of Medtronic in the 3rd quarter valued at about $31,000. Finally, Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Medtronic during the 3rd quarter worth about $33,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.26% of the company’s stock.

Medtronic Price Performance

MDT stock opened at $88.50 on Wednesday. The firm has a market cap of $113.62 billion, a P/E ratio of 24.65, a price-to-earnings-growth ratio of 2.26 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The stock has a 50-day simple moving average of $97.54 and a 200-day simple moving average of $96.85.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.Medtronic’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. The ex-dividend date is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.2%. Medtronic’s dividend payout ratio (DPR) is currently 79.11%.

Analyst Ratings Changes

MDT has been the topic of several research reports. Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a report on Sunday, March 1st. Truist Financial decreased their price objective on shares of Medtronic from $107.00 to $103.00 and set a “hold” rating for the company in a research note on Wednesday, February 18th. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. UBS Group reissued a “neutral” rating and issued a $104.00 target price on shares of Medtronic in a research note on Wednesday, February 4th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and a consensus price target of $110.74.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).